Document Detail


Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
MedLine Citation:
PMID:  17612935     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia. We evaluated the incidence of lymphopenia and opportunistic infections during treatment and up to 12 months following treatment discontinuation in a cohort of 39 patients receiving temozolomide for advanced neuroendocrine tumors. The incidence of Grade 3-4 lymphopenia was 46 percent after 4 months of therapy and remained at 30 percent or greater for 12 months following treatment discontinuation. The overall incidence of opportunistic infections was 10 percent, while among patients receiving therapy for > or =7 months, the incidence was 20 percent. Prophylaxis for Pneumocystis jiroveci pneumonia and varicella-zoster, as well as cytomegalovirus monitoring, should be considered in patients receiving temozolomide-based treatment.
Authors:
Abraham B Schwarzberg; Elizabeth H Stover; Tanya Sengupta; Ann Michelini; Michele Vincitore; Lindsey R Baden; Matthew H Kulke
Related Documents :
388085 - The value of prophylactic antibiotics in aorat-coronary bypass operations: a double-bli...
696155 - The effect on total antimicrobial consumption and hospitalization time after prophylact...
17011845 - Efficacy of oral antiviral prophylaxis in preventing ocular herpes simplex virus recurr...
6357175 - The prevention of postappendicectomy sepsis by metronidazole and cotrimoxazole: a contr...
1833245 - Medical treatment of endometriosis: a comparison of the suppressive effects of danazol ...
21157975 - Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleedi...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer investigation     Volume:  25     ISSN:  0735-7907     ISO Abbreviation:  Cancer Invest.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-07-06     Completed Date:  2007-08-21     Revised Date:  2014-01-31    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  249-55     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents, Alkylating / adverse effects*
Cytomegalovirus Infections / etiology
Dacarbazine / adverse effects,  analogs & derivatives*
Female
Herpes Zoster / etiology
Humans
Incidence
Lymphopenia / chemically induced*,  epidemiology
Male
Middle Aged
Neuroendocrine Tumors / drug therapy*
Opportunistic Infections / etiology*
Pneumonia, Pneumocystis / etiology
Grant Support
ID/Acronym/Agency:
K23 CA093401/CA/NCI NIH HHS; K30 HL04095/HL/NHLBI NIH HHS; T32 GM007753/GM/NIGMS NIH HHS; T32GM07753-24/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 7GR28W0FJI/Dacarbazine; 85622-93-1/temozolomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and ...
Next Document:  Transcriptional profile of Ki-Ras-induced transformation of thyroid cells.